Read Time:10 Second
Biogen’s stock fell more than 6% premarket on Friday after European regulators gave a thumbs down to the company’s Alzheimer’s disease treatment, which it markets jointly with Eisai Co. Ltd.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
